An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

NCT07583953 | Not Yet Recruiting Early Phase 1

• 1 other identifier: ABO2109-004
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.

Conditions

Solid Tumors

Keywords

The First Affiliated Hospital of Soochow University

Outcome Measures

Primary Outcomes (4)

• Incidence and nature of dose-limiting toxicity (DLT) with ABO2109 monotherapy (Dose Exploration)

  From the first dose of ABO2109 through 21 days post-dose for each dose-escalation cohort

• Incidence and severity of TEAE, TESAE, and TEAE leading to study treatment interruption or premature discontinuation following study treatment (Dose Exploration)

  From the start of study intervention until 30 days after the last dose of ABO2109/90 days after the last dose of toripalimab, or until the initiation of new antineoplastic therapy, whichever occurs first

• Changes in ECOG performance status score (Dose Exploration)

  From baseline until 30 days after the last dose of ABO2109/90 days after the last dose of toripalimab, or until the initiation of new antineoplastic therapy, whichever occurs first

• DFS based on RECIST Version 1.1. (Dose Expansion)

  3 years

Study Arms (2)

Dose Exploration Part

EXPERIMENTAL

Participants will receive ABO2109 at specified dose defined in the study protocol via an intramuscular (IM) injection every three weeks. The first treatment cycle consists of ABO2109 monotherapy, and combination therapy with toripalimab is initiated from the second treatment cycle onwards.

Biological: ABO2109 Injection;Toripalimab

Dose Expansion Part

EXPERIMENTAL

Participants will receive ABO2109 via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and Toripalimab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 13 cycles, whichever is sooner.

Biological: ABO2109 Injection;Toripalimab

Interventions

ABO2109 Injection;Toripalimab BIOLOGICAL

Drug: ABO2109 Injection personalized cancer vaccine Drug: Toripalimab Anti-PD-1 monoclonal antibody

Dose Exploration Part

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥18 years of age at time of informed consent
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
• Life expectancy of ≥6 months
• Patient diagnosed with solid tumors and is receiving perioperative and/or adjuvant anti-cancer therapy.
• Sufficient organ function
• Female patients must meet both of the criteria: a) Surgically sterile, or postmenopausal for ≥2 years, or women of childbearing potential with a negative pregnancy test and willing to use effective contraception during the study and for at least 90 days after the last study dose. Use of progesterone-containing contraceptives is not permitted. b) Agree not to breastfeed during the study and for at least 90 days after the last study dose.Male patients must meet the following criteria:If not surgically sterile and potentially engaging in sexual activity that could lead to pregnancy, agree to use effective contraception during the study and for at least 90 days after the last study dose.

You may not qualify if:

• For perioperative or adjuvant therapy setting, participants have received systemic anti-tumor treatment previously
• Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that has been cured, or superficial bladder cancer, carcinoma in situ of the breast, carcinoma in situ of the cervix, thyroid cancer
• Active or prior history of interstitial lung disease, tuberculosis, or any other condition known to compromise pulmonary function.
• Active infections
• History of severe cardiovascular or cerebrovascular diseases occurring within 6-month prior to study treatment
• Known hypersensitivity to the active ingredients or excipients of ABO2109 or toripalimab
• Positive pregnancy test or lactating women

Sponsors & Collaborators

• Suzhou Abogen Biosciences Co., Ltd.: lead
• The First Affiliated Hospital of Soochow University: collaborator

Central Study Contacts

Wei Li

CONTACT

+86 15895401045; liwei10@suda.edu.cn

shi hui Fu

CONTACT

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2026
• First Posted: May 13, 2026
• Study Start: April 17, 2026
• Primary Completion (Estimated): January 31, 2029
• Study Completion (Estimated): April 17, 2031
• Last Updated: May 13, 2026

Record last verified: 2026-05